{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T08:47:10Z","timestamp":1782982030990,"version":"3.54.5"},"reference-count":110,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Vaccines and Immunotherapy"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:p>Cervical cancer remains a primary cause of gynecologic oncology-related mortality globally, with a disproportionate burden in sub-Saharan Africa. The pathogenesis of the disease is fundamentally driven by persistent infection with high-risk human papillomavirus (HPV) genotypes, most notably HPV-16 and HPV-18. The evolution of prophylactic HPV vaccination has transformed preventive oncology, progressing from first-generation bivalent and quadrivalent formulations to the nonavalent vaccine, which extended protection to five additional oncogenic types. These vaccines, composed of L1 virus-like particles (VLPs), induce robust and durable humoral and cellular immune responses, leading to population-level reductions of up to 98% in vaccine-type infections and 80% in high-grade cervical lesions. To address persistent global health disparities, regionally produced, cost-effective alternatives such as Cecolin and Cervavac have been introduced to enhance accessibility within low- and middle-income countries. This shift toward broader coverage is further supported by the 2022 WHO recommendation for a single-dose schedule, aimed at optimizing resource-limited immunization programs. Current research is now pivoting toward next-generation candidates targeting the conserved L2 protein for pan-genotype protection, as well as therapeutic vaccines targeting E6 and E7 oncoproteins to clear established infections. However, achieving the WHO\u2019s 2030 cervical cancer elimination targets remains contingent upon overcoming infrastructural, cultural, and informational barriers that hinder vaccine uptake. This review synthesizes the molecular composition and immunological mechanisms of current and emerging HPV vaccines, evaluating their clinical efficacy and the systemic strategies required to ensure equitable global access.<\/jats:p>","DOI":"10.1177\/25151355261449446","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T06:22:16Z","timestamp":1782800536000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Innovations in HPV vaccination and their role in global cervical cancer control: a review"],"prefix":"10.1177","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7325-1167","authenticated-orcid":false,"given":"Agapiti","family":"H. Chuwa","sequence":"first","affiliation":[{"name":"Mbeya College of Health and Allied Sciences, University of Dar es Salaam, P. O. Box 608, Mbeya, Tanzania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01097-3"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12985-025-02858-9"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1042\/CS20160786"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.05028-11"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpobgyn.2017.08.015"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604972"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-025-11657-0"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-23-1266"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11051432"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-06896-3"},{"key":"e_1_3_4_12_2","article-title":"Immunocytes in the tumor microenvironment: recent updates and interconnections","volume":"16","author":"Yu J","year":"2025","unstructured":"Yu J, Fu L, Wu R, et al. Immunocytes in the tumor microenvironment: recent updates and interconnections. Front Immunol 2025; 16: 1517959.","journal-title":"Front Immunol"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.3390\/cimb47090759"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.645299"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-12920-4"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13027-024-00573-8"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2025.127015"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.3390\/v17091209"},{"key":"e_1_3_4_19_2","first-page":"300","article-title":"Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices","volume":"64","author":"Petrosky E","year":"2015","unstructured":"Petrosky E, Bocchini JAJr, Hariri S, et al. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep 2015; 64: 300\u2013304.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2023.10.041"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2022.994743"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0901474"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2018.1516552"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines13010092"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2414514122"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1591297"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2025.126817"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2018.13"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10010053"},{"key":"e_1_3_4_30_2","first-page":"2528","article-title":"A therapeutic vaccine targeting HPV E6\/E7 with intrinsic toll-like receptor 2 agonist activity induces antitumor immunity","volume":"8","author":"Sher YP","year":"2018","unstructured":"Sher YP, Lee C, Liu SY, et al. A therapeutic vaccine targeting HPV E6\/E7 with intrinsic toll-like receptor 2 agonist activity induces antitumor immunity. Am J Cancer Res 2018; 8: 2528\u20132537.","journal-title":"Am J Cancer Res"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-069616"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9121413"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12121356"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.04.108"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2023-004275"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(24)00477-7"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10020256"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2022-060993"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2021.1908059"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60920-X"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(25)00031-3"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(23)00275-X"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00480-1"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines13080846"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2016.03.016"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12985-024-02397-9"},{"key":"e_1_3_4_47_2","first-page":"101","article-title":"Update on safety and efficacy of HPV vaccines: focus on gardasil","volume":"10","author":"Soliman M","year":"2021","unstructured":"Soliman M, Oredein O, Dass CR. Update on safety and efficacy of HPV vaccines: focus on gardasil. Int J Mol Cell Med 2021; 10: 101\u2013113.","journal-title":"Int J Mol Cell Med"},{"key":"e_1_3_4_48_2","first-page":"399","article-title":"Update on the new 9-valent vaccine for human papillomavirus prevention","volume":"62","author":"Yang DY","year":"2016","unstructured":"Yang DY, Bracken K. Update on the new 9-valent vaccine for human papillomavirus prevention. Can Fam Physician Med Fam Can 2016; 62: 399\u2013402.","journal-title":"Can Fam Physician Med Fam Can"},{"key":"e_1_3_4_49_2","unstructured":"CDC. Human papillomavirus (HPV) vaccine safety 2025."},{"key":"e_1_3_4_50_2","volume-title":"Cecolin\u00ae recombinant human papillomavirus bivalent (types 16, 18) Vaccine","author":"WHO","year":"2025","unstructured":"WHO. WHO PUBLIC ASSESSMENT REPORT (WHOPAR). Cecolin\u00ae recombinant human papillomavirus bivalent (types 16, 18) Vaccine. Xiamen Innovax Biotech Co., Ltd., China, 2025."},{"key":"e_1_3_4_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jped.2025.04.009"},{"key":"e_1_3_4_52_2","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2023.2184756"},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2023.2281700"},{"key":"e_1_3_4_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.04.019"},{"key":"e_1_3_4_55_2","doi-asserted-by":"publisher","DOI":"10.2147\/ITT.S451659"},{"key":"e_1_3_4_56_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-024-03701-8"},{"key":"e_1_3_4_57_2","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2024.1762"},{"key":"e_1_3_4_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.02.003"},{"key":"e_1_3_4_59_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10552-022-01662-y"},{"key":"e_1_3_4_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.100836"},{"key":"e_1_3_4_61_2","doi-asserted-by":"publisher","DOI":"10.1186\/s41256-024-00380-z"},{"key":"e_1_3_4_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2025.127560"},{"key":"e_1_3_4_63_2","doi-asserted-by":"publisher","DOI":"10.1002\/bit.28703"},{"key":"e_1_3_4_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jip.2011.05.004"},{"key":"e_1_3_4_65_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.20-1650"},{"key":"e_1_3_4_66_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-024-19485-8"},{"key":"e_1_3_4_67_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-2667(23)00180-9"},{"key":"e_1_3_4_68_2","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines13050433"},{"key":"e_1_3_4_69_2","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2025.1892"},{"key":"e_1_3_4_70_2","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12050489"},{"key":"e_1_3_4_71_2","doi-asserted-by":"publisher","DOI":"10.2217\/WHE.10.74"},{"key":"e_1_3_4_72_2","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2020-001285"},{"key":"e_1_3_4_73_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30647-3"},{"key":"e_1_3_4_74_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02658-0"},{"key":"e_1_3_4_75_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.09.057"},{"key":"e_1_3_4_76_2","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12090956"},{"key":"e_1_3_4_77_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103290"},{"key":"e_1_3_4_78_2","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12070746"},{"key":"e_1_3_4_79_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-018-0544-4"},{"key":"e_1_3_4_80_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pmedr.2022.101734"},{"key":"e_1_3_4_81_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2024.01.094"},{"key":"e_1_3_4_82_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10051044"},{"key":"e_1_3_4_83_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1010790"},{"key":"e_1_3_4_84_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1272018"},{"key":"e_1_3_4_85_2","doi-asserted-by":"crossref","unstructured":"Bei L Gao S Zhao D et al. Immunogenicity assessment of a 14-valent human papillomavirus vaccine candidate in mice. Vaccines (Basel) 2024; 12: 1262.","DOI":"10.3390\/vaccines12111262"},{"key":"e_1_3_4_86_2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00566-22"},{"key":"e_1_3_4_87_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00239-1"},{"key":"e_1_3_4_88_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.990877"},{"key":"e_1_3_4_89_2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000612"},{"key":"e_1_3_4_90_2","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2021.1893036"},{"key":"e_1_3_4_91_2","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0000000000001235"},{"key":"e_1_3_4_92_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2018.05.011"},{"key":"e_1_3_4_93_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2022.12.003"},{"key":"e_1_3_4_94_2","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9111262"},{"key":"e_1_3_4_95_2","article-title":"Current status and future directions for the development of human papillomavirus vaccines","volume":"15","author":"Wang R","year":"2024","unstructured":"Wang R, Huang H, Yu C, et al. Current status and future directions for the development of human papillomavirus vaccines. Front Immunol 2024; 15: 1362770.","journal-title":"Front Immunol"},{"key":"e_1_3_4_96_2","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12111291"},{"key":"e_1_3_4_97_2","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2018.1512453"},{"key":"e_1_3_4_98_2","doi-asserted-by":"publisher","DOI":"10.4103\/jfmpc.jfmpc_235_24"},{"key":"e_1_3_4_99_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-2667(20)30006-2"},{"key":"e_1_3_4_100_2","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2018.23.41.1700737"},{"key":"e_1_3_4_101_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00535-1"},{"key":"e_1_3_4_102_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pvr.2017.12.006"},{"key":"e_1_3_4_103_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2025.126841"},{"key":"e_1_3_4_104_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.918331"},{"key":"e_1_3_4_105_2","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkad101"},{"key":"e_1_3_4_106_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2019.03.250"},{"key":"e_1_3_4_107_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-1662"},{"key":"e_1_3_4_108_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1037124"},{"key":"e_1_3_4_109_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-022-02199-y"},{"key":"e_1_3_4_110_2","article-title":"Public health approach in the elimination and control of cervical cancer: a review","volume":"15","author":"Jallah JK","year":"2023","unstructured":"Jallah JK, Anjankar A, Nankong FA. Public health approach in the elimination and control of cervical cancer: a review. Cureus 2023; 15: e44543.","journal-title":"Cureus"},{"key":"e_1_3_4_111_2","article-title":"Trends in uptake and impact of thermostable vaccines in Africa","volume":"13","author":"Kitui SK","year":"2025","unstructured":"Kitui SK, Juma E, Ndalama MT, et al. Trends in uptake and impact of thermostable vaccines in Africa. Ther Adv Vaccin Immunother 2025; 13: 25151355251341662.","journal-title":"Ther Adv Vaccin Immunother"}],"container-title":["Therapeutic Advances in Vaccines and Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/25151355261449446","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/25151355261449446","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/25151355261449446","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T08:16:14Z","timestamp":1782980174000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/25151355261449446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":110,"alternative-id":["10.1177\/25151355261449446"],"URL":"https:\/\/doi.org\/10.1177\/25151355261449446","relation":{},"ISSN":["2515-1355","2515-1363"],"issn-type":[{"value":"2515-1355","type":"print"},{"value":"2515-1363","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"article-number":"25151355261449446"}}